Paper1663283
In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
Ji B and 2 others. Tubercle, 1991. Cited by 38 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Papers, record 1663283. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1663283
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Infective Agents | Major topic |
| Fluoroquinolones | Major topic |
| Mycobacterium tuberculosis | Major topic |
| Quinolones | Major topic |
| Animals | |
| Dose-Response Relationship, Drug | |
| Female | |
| Mice | |
| Microbial Sensitivity Tests | |
| Ofloxacin | |
| Tuberculosis |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 24,550,337 | Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24550337 | PubMed |
| 11,120,969 | Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11120969 | PubMed |
| 10,898,685 | Antimycobacterial activities of novel levofloxacin analogues. | Antimicrob Agents Chemother | 2000 | https://conductscience.org/library/papers/10898685 | PubMed |
| 9,869,570 | Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. | Antimicrob Agents Chemother | 1999 | https://conductscience.org/library/papers/9869570 | PubMed |
| 9,687,411 | Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9687411 | PubMed |
| 9,687,408 | In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9687408 | PubMed |
| 9,559,785 | Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9559785 | PubMed |
| 9,056,001 | Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9056001 | PubMed |
| 8,452,346 | In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8452346 | PubMed |
| 8,384,811 | Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8384811 | PubMed |
| 8,285,617 | Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8285617 | PubMed |
| 7,979,275 | Activity of levofloxacin in a murine model of tuberculosis. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/7979275 | PubMed |
| 7,793,885 | Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/7793885 | PubMed |
| 7,741,981 | Avoidance and management of adverse reactions to antituberculosis drugs. | Drug Saf | 1995 | https://conductscience.org/library/papers/7741981 | PubMed |
| 7,574,527 | In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/7574527 | PubMed |
| 7,486,904 | Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/7486904 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1663283
GET https://conductscience.org/api/papers/v1/1663283/authors